A recent study reveals that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who end conventional lifestyle plans.
Findings released in a prominent medical journal shows that while obese individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month after stopping.
"People buying these drugs need to be aware of the risk of rapid rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about 18 months.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through lifestyle changes alone usually have a slower creep back—approximately 100 grams monthly—after stopping.
Explaining the Rapid Regain
Nutrition scientists suggest the way of the jabs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to appetite is uncontrolled, making overeating a significant risk."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, given the significant potential of weight regain, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who note that the findings "highlight the persistent character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Users who have stopped the medication describe a powerful resurgence of hunger.
"It was like a switch activating and I was suddenly extremely hungry," said one woman.
This challenge is worsened if users have not established lasting lifestyle or habit modifications during treatment.
Widespread Use
Figures show that a significant number of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while these medications are powerful tools for weight loss, they are not a standalone fix and long-term success hinges on ongoing behavioural support.
